Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial
Tian-mei Zeng , Tian-yi Jiang , Guang Yang , Zhuo Cheng , Cheng Lou , Wei Wei , Chen-jie Tao , Shouzi Hu , Hui Wang , Xiao-wen Cui , Ye-xiong Tan , Li-wei Dong , Hong-yang Wang , Zhen-gang Yuan
Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1675
Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial
• There is a limited strategy for the second-line option of intrahepatic cholangiocarcinoma (ICC). • This investigator-initiated phase 2 study evaluated bortezomib in ICC patients with phosphatase and tension homology deficiency. • The overall response rate was 18.75% and the overall survival was 7.2 months in the intent-to-treat cohort. • These results justify further developing bortezomib in ICC patients with PTEN deficiency.
bortezomib / intrahepatic cholangiocarcinoma / PTEN
2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
/
| 〈 |
|
〉 |
PDF
